Literature DB >> 29305065

High macrophage PD-L1 expression not responsible for T cell suppression.

Naomi Goldman1, Yelizavet D Lomakova1, Jennifer Londregan1, Amanda Bucknum1, Kelley DePierri1, John Somerville1, James E Riggs2.   

Abstract

Tumors are often comprised of microenvironments (TMEs) with a high proportion of cells and molecules that regulate immunity. Peritoneal cavity (PerC) cell culture reproduces key features of TMEs as lymphocyte proliferation is suppressed by PerC macrophages (Mϕs). We monitored the expression of T cell stimulatory (Class II MHC, B7) and inhibitory (PD-L1) molecules by PerC APCs before and after culture and report here that IFNγ-driven PD-L1 expression increased markedly on PerC Mϕs after TCR ligation, even more so than seen with direct APC activation by LPS. Considering the high APC composition of and pronounced PD-L1 expression by PerC cells, it was surprising that blocking PD-1/PD-L1 interaction by mAb neutralization or genetic ablation did not relieve suppression. This result parallels TME challenges observed in the clinic and validates the need for further study of this culture model to inform strategies to promote anti-tumor immunity.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Macrophage; PD-L1; Suppression; T cell

Mesh:

Substances:

Year:  2017        PMID: 29305065      PMCID: PMC5808909          DOI: 10.1016/j.cellimm.2017.12.013

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  38 in total

Review 1.  Lymphoid stroma in the initiation and control of immune responses.

Authors:  Scott N Mueller; Rafi Ahmed
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

Review 2.  Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.

Authors:  Takami Sato; Mizue Terai; Yutaka Tamura; Vitali Alexeev; Michael J Mastrangelo; Senthamil R Selvan
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.

Authors:  Tomohide Yamazaki; Hisaya Akiba; Akemi Koyanagi; Miyuki Azuma; Hideo Yagita; Ko Okumura
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

Review 5.  Tumor microenvironment: The culprit for ovarian cancer metastasis?

Authors:  Zhongyue Luo; Qiu Wang; Wayne Bond Lau; Bonnie Lau; Lian Xu; Linjie Zhao; Huiliang Yang; Min Feng; Yu Xuan; Yanfei Yang; Lingzi Lei; Chenlu Wang; Tao Yi; Xia Zhao; Yuquan Wei; Shengtao Zhou
Journal:  Cancer Lett       Date:  2016-04-27       Impact factor: 8.679

Review 6.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

Review 8.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

9.  Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice.

Authors:  Benfan Wang; Qinyan Li; Li Qin; Siting Zhao; Jinyan Wang; Xiaoping Chen
Journal:  BMC Immunol       Date:  2011-08-04       Impact factor: 3.615

10.  Macrophages in human breast disease: a quantitative immunohistochemical study.

Authors:  P M Kelly; R S Davison; E Bliss; J O McGee
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

View more
  4 in total

1.  Eosinophils downregulate lung alloimmunity by decreasing TCR signal transduction.

Authors:  Oscar Okwudiri Onyema; Yizhan Guo; Bayan Mahgoub; Qing Wang; Amir Manafi; Zhongcheng Mei; Anirban Banerjee; Dongge Li; Mark H Stoler; Melissa T Zaidi; Adam G Schrum; Daniel Kreisel; Andrew E Gelman; Elizabeth A Jacobsen; Alexander Sasha Krupnick
Journal:  JCI Insight       Date:  2019-06-06

2.  PHA eludes macrophage suppression to activate CD8+ T cells.

Authors:  Yelizavet D Lomakova; Jennifer Londregan; Jeffrey Maslanka; Naomi Goldman; John Somerville; James E Riggs
Journal:  Immunobiology       Date:  2018-11-03       Impact factor: 3.144

Review 3.  Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.

Authors:  Tao Wang; Desirée Denman; Silvia M Bacot; Gerald M Feldman
Journal:  Biomedicines       Date:  2022-05-20

4.  Genomic and molecular features distinguish young adult cancer from later-onset cancer.

Authors:  William Lee; Zishan Wang; Miriam Saffern; Tomi Jun; Kuan-Lin Huang
Journal:  Cell Rep       Date:  2021-11-16       Impact factor: 9.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.